Verve Therapeutics Statistics Share Statistics Verve Therapeutics has 89.14M
shares outstanding. The number of shares has increased by 5.34%
in one year.
Shares Outstanding 89.14M Shares Change (YoY) 5.34% Shares Change (QoQ) 0.39% Owned by Institutions (%) 93.01% Shares Floating 65.37M Failed to Deliver (FTD) Shares 1,484 FTD / Avg. Volume 0.03%
Short Selling Information The latest short interest is 3.63M, so 4.06% of the outstanding
shares have been sold short.
Short Interest 3.63M Short % of Shares Out 4.06% Short % of Float 4.81% Short Ratio (days to cover) 1.39
Valuation Ratios The PE ratio is -2.4 and the forward
PE ratio is -3.58.
Verve Therapeutics's PEG ratio is
0.1.
PE Ratio -2.4 Forward PE -3.58 PS Ratio 14.78 Forward PS 61.8 PB Ratio 0.97 P/FCF Ratio -2.96 PEG Ratio 0.1
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Verve Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 12.65,
with a Debt / Equity ratio of 0.14.
Current Ratio 12.65 Quick Ratio 12.65 Debt / Equity 0.14 Debt / EBITDA -0.32 Debt / FCF -0.43 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $118K Profits Per Employee $-725.22K Employee Count 274 Asset Turnover 0.05 Inventory Turnover n/a
Taxes Income Tax 349K Effective Tax Rate -0.18%
Stock Price Statistics The stock price has increased by 138.84% in the
last 52 weeks. The beta is 2.24, so Verve Therapeutics's
price volatility has been higher than the market average.
Beta 2.24 52-Week Price Change 138.84% 50-Day Moving Average 8.21 200-Day Moving Average 6.45 Relative Strength Index (RSI) 76.24 Average Volume (20 Days) 5,716,259
Income Statement In the last 12 months, Verve Therapeutics had revenue of 32.33M
and earned -198.71M
in profits. Earnings per share was -2.36.
Revenue 32.33M Gross Profit 32.33M Operating Income -228.66M Net Income -198.71M EBITDA -221.91M EBIT -228.66M Earnings Per Share (EPS) -2.36
Full Income Statement Balance Sheet The company has 172.56M in cash and 69.98M in
debt, giving a net cash position of 102.58M.
Cash & Cash Equivalents 172.56M Total Debt 69.98M Net Cash 102.58M Retained Earnings -743.01M Total Assets 614.16M Working Capital 459.67M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -157.69M
and capital expenditures -3.74M, giving a free cash flow of -161.43M.
Operating Cash Flow -157.69M Capital Expenditures -3.74M Free Cash Flow -161.43M FCF Per Share -1.91
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -707.23% and -614.59%.
Gross Margin 100% Operating Margin -707.23% Pretax Margin -613.51% Profit Margin -614.59% EBITDA Margin -686.34% EBIT Margin -707.23% FCF Margin -499.28%
